Venetoclax, the First BCL-2 Inhibitor for Use in Patients With Chronic Lymphocytic Leukemia

被引：0
|
作者：
Seymour, John [1 ,2 ,3 ]
机构：
[1] Peter MacCallum Canc Ctr, Clin Res, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Vic, Australia
[3] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2019年 / 17卷 / 08期
关键词：
NAVITOCLAX; RITUXIMAB;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：440 / 443
页数：4
相关论文
共 50 条
  • [21] Venetoclax for the treatment of patients with chronic lymphocytic leukemia
    Crombie, Jennifer
    Davids, Matthew S.
    FUTURE ONCOLOGY, 2017, 13 (14) : 1223 - 1232
  • [22] Bcl-2 family gene expression and Bcl-2 phopshorylation status in chronic lymphocytic leukemia.
    Viswanathan, S
    Saxena, A
    FASEB JOURNAL, 1998, 12 (05): : A810 - A810
  • [23] VSV Oncolysis in Combination With the BCL-2 Inhibitor Obatoclax Overcomes Apoptosis Resistance in Chronic Lymphocytic Leukemia
    Samuel, Sara
    Tumilasci, Vanessa F.
    Oliere, Stephanie
    Nguyen, Thi Lien-Anh
    Shamy, April
    Bell, John
    Hiscott, John
    MOLECULAR THERAPY, 2010, 18 (12) : 2094 - 2103
  • [24] Prognostic significance of bcl-2 expression in chronic lymphocytic leukemia.
    Mapara, MY
    Bommert, K
    Bargou, R
    Daniel, PT
    Stilgenbauer, S
    Benner, A
    Lichter, P
    Dorken, B
    Dohner, H
    BLOOD, 1997, 90 (10) : 398 - 398
  • [25] Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia
    Del Principe, Maria Ilaria
    Dal Bo, Michele
    Bittolo, Tamara
    Buccisano, Francesco
    Rossi, Francesca Maria
    Zucchetto, Antonella
    Rossi, Davide
    Bomben, Riccardo
    Maurillo, Luca
    Cefalo, Mariagiovanna
    De Santis, Giovanna
    Venditti, Adriano
    Gaidano, Gianluca
    Amadori, Sergio
    de Fabritiis, Paolo
    Gattei, Valter
    Del Poeta, Giovanni
    HAEMATOLOGICA, 2016, 101 (01) : 77 - 85
  • [26] Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells
    Campas, Clara
    Cosialls, Ana M.
    Barragan, Montserrat
    Iglesias-Serret, Daniel
    Santidrian, Antonio F.
    Coll-Mulet, Llorenc
    de Frias, Merce
    Domingo, Alicia
    Pons, Gabriel
    Gil, Joan
    EXPERIMENTAL HEMATOLOGY, 2006, 34 (12) : 1663 - 1669
  • [27] Use of Venetoclax Combination Regimens in Chronic Lymphocytic Leukemia
    Tam, Constantine S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 504 - 506
  • [28] The BCL-2 Inhibitor Venetoclax Is Associated with Mobilization Failures
    Cooling, Laura
    Phillips, Tycel
    Hoffmann, Sandra
    Davis, Kristina
    Yamada, Chisa
    Davenport, Robertson
    TRANSFUSION, 2020, 60 : 131A - 131A
  • [29] Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax
    Avsec, Damjan
    Skrlj Miklavcic, Marja
    Burnik, Tilen
    Kanduser, Masa
    Bizjak, Marusa
    Podgornik, Helena
    Mlinaric-Rascan, Irena
    CELL DEATH & DISEASE, 2022, 13 (10)
  • [30] Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax
    Damjan Avsec
    Marja Škrlj Miklavčič
    Tilen Burnik
    Maša Kandušer
    Maruša Bizjak
    Helena Podgornik
    Irena Mlinarič-Raščan
    Cell Death & Disease, 13
12345